Primary progressive aphasia (PPA) is a rare neurological syndrome that gradually impairs a person’s language. Baycrest Canada ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 ...

Kuick Research Report highlights ongoing Clinical Development Technology platforms In Recent Research Study On KIF18A ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical ...

Farber, with the creation of a new cancer hospital, is moving forward after the completion of the regulatory process.

XyloCor Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapies for cardiovascular disease, announced the first patient has been dosed in the Phase 2b EXACT-2 ...

A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

The initial implementation phase of myUABResearch, the university’s new electronic research administration system, is on ...

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile ...

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.

A recent study found that only 15% of cancer survivors discussed trials with their healthcare providers, with ...